Clinical trial
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
NCT01177683 is registered in ClinicalTrials.gov with Sherif Farag, MB, BS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
- Lead sponsor
- Sherif Farag, MB, BS
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- July 31, 2010
- Completion date
- December 31, 2017
- Enrollment
- 32 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.